Xuefeng YU, co-founder of CanSino Biologics, was appointed executive director on January 13, 2009. He has also served as Chief Executive Officer (CEO) since January 2009. He is primarily responsible for overseeing strategic development, overall operations and management as well as being the major decision-making force of our company. In addition, Dr. Yu is also responsible for managing our commercial operations center. He has more than 30 years' experience in biotech research and development. From September 1990 to June 1991, Dr. Yu worked as a lecturer in the Biology Department at Nankai University. From 1996 to 1998, he served as staff scientist at IBEX Technologies, Inc. (a company listed on the Toronto Stock Exchange Venture Exchange, ticker symbol: IBT). Dr. Yu joined Sanofi Pasteur in May 1998 and held the position of director of fermentation development in Canada when he left the company in August 2009.
Shou Bai CHAO, became executive director on June 22, 2018 and Chief Operating Officer （COO）on May 1, 2018. He is deputy general manager of our company and is primarily responsible for the management of daily operations and strategy development. In addition, Dr. Chao also oversees production management and quality control. With nearly 33 years' experience in the biotechnology industry, he formerly served as Vice President and Senior Vice President at AstraZeneca plc from January 2008 to April 2018, and was president and the Board Director at the Chinese Biopharmaceutical Association-USA from June 2014 to June 2016.
Tao ZHU is a co-founder of our company. Dr. Zhu was appointed as executive director on January 13, 2009 and has served as the chief scientific officer since January 2009. He is primarily responsible for leading vaccine research and development for CanSinoBIO. In addition, Dr. Zhu also oversees the management of regulatory and clinical affairs. Together with experts from the Academy of Military Medical Sciences, Dr. Zhu led the development and pre-clinical research of the only available recombinant ebola vaccine in China, the production of which was approved by the CFDA. He also led the combinational vaccine project and PBPV project, both of which have been selected as one of the major science and technology projects in the National Twelfth Five-Year Plan for “Significant New Drug Creation” . His achievements also include the establishment of a conjugation technology platform and the development of a variety of vectors including CRM197, plus the process development, pre-clinical research and clinical application of several products, including MCV4, and the invention of seven patents in the PRC.
Jing WANG, was appointed as Chief Financial Officer on 27th Mar, 2020, and has been the secretary of the Board since February 2017. Ms. Wang joined the Company in June 2012, and held several positions before she was appointed as CFO. Ms. Wang has led the establishment of our financing, financial management, human resources and administration systems as well as completing the Pre-IPO fundraising of approximately 743 million RMB. Ms.Wang successfully led the company IPO on main board of HongKong Exchange. From July 2005 to May 2012, Ms. Wang worked at several subsidiaries of Tasly Holding Group Co., Ltd., where she was responsible for business development of pharmaceutical products, including vaccines in domestic and overseas markets. From March 2002 to June 2005, Ms. Wang worked at Sinochem Tianjin Import and Export Corporation. Ms. Wang has a bachelor degree in Economics, a master degree in Engineering of Peking University, Global EMBA of CEIBS.
Pierre Armand MORGON joined the company as Senior Vice President of International Business Operation in 2020. Pierre has over 30 years of experience in the global life science industry, especially with specialty care, vaccines and immunotherapy, at the helm of international operations, in C-level positions at global level in multinational corporations and as CEO of start-up companies. Currently, Pierre also serves as CEO of MRGN Advisors and Regional Partner for Switzerland at Mérieux Equity Partners. He is Chairman of the Boards of Theradiag and of Eurocine Vaccines, as well as Non-Executive Director to the Boards of Vaccitech and Univercells. Additionally, he is a lecturer in several MBA programs and in life science conferences, and at the Mass Challenge incubator in Switzerland where he is also a mentor for start-up life sciences companies. Pierre holds a Doctorate of Pharmacy, a Master in Business Law and a MBA. He is also an alumnus of INSEAD and IMD.
Lifeng XU, was appointed vice president for Regulatory Affairs. Ms.Xu has 27 years’experience in product development, regulatory affairs and project management of vaccines, such as the preventive and therapeutic hepatitis B vaccine, MMR ( measles, mumps and rubella) vaccine, rabies vaccine and varicella vaccine, etc. Prior to joining CanSinoBIO, she held the position of deputy director of Research and Registration at CNBG. There she led her team in obtaining three new drug licenses and two CTAs. Before joining the bio-pharmaceutical industry, Ms.Xu earned a medical degree and worked at Chengde Hospital as an internist for 5 years.
Zhongqi SHAO, was appointed vice president for Vaccine Research. Dr. Shao joined CanSino in 2011 as VP of R&D. He is responsible for new antigen discovery and expression, proof of concept studies on new vaccine candidates, as well as analytical science and assay development. Dr. Shao received his Ph.D. in bacterial physiology from Concordia University, and worked as a post-doctoral research fellow at the Soils and Crops Research and Development Centre, Agriculture and Agri-Food Canada.
Liesheng CHEN, was appointed vice president at the Production Centre. He graduated from East China University of Science and Technology and has 30 years' experience in biological products production management. He formerly worked at the Shanghai Institute of Biological Products research center, Shanghai Rongsheng Biotech CO., LTD., and Walvax Biotechnology Co., Ltd. where he participated in a number of vaccine research projects as well as carrying out developmental and industrialisation work.
Xiaoman DONG, was appointed as vice president of the Quality Centre. Ms. Dong graduated from Xi'an Jiao Tong University, and has impressive industry experience with more than 30 years working on biological product quality management systems. She formerly worked at the Lanzhou Institute of Biological Products, Beijing Tiantan Biological Products Co. Ltd., Jiangsu Walvax Biotech Company, and was former researcher, vaccine quality manager, quality authorisation manager, and deputy general manager. Ms. Dong has overseen vaccine quality management projects several times, including 15 GMP certifications and re-certifications of vaccine products. She also led quality management operations for multiple vaccine raw liquid and freeze-dried preparation workshops while processing the design, construction, verification, and carrying out trial production and operation.
Guojun ZHAO, vice president of CANSINOBIO, responsible for sales. Mr. Zhao holds a master's degree in business administration from Tsinghua University. He was deputy general manager and head of sales in Beijing Tiantan Biological products Co., Ltd ("Tiantan Biology", stock code: 600161.SH). He has been responsible for the sales and management of vaccine for more than 30 years in China National Biotec Group Company Limited and its enterprises,National Vaccine &Serum Institute, etc.
Yonghui WU, was appointed as vice president of the Marketing Department. Mr. Wu has a master's degree in business administration from the University of International Business and Economics, and a bachelor's degree in preventive medicine from Beijing Medical University. With nearly 25 years of experience in the bio-pharmaceutical market, Mr. Wu has previously worked at Sanofi-Pasteur, Beijing Novartis Pharma, Beijing Boya Wei-ming United Stem Cell Technology Co., Ltd., Beijing Renhe Huatai Technology Co., Ltd., Beijing Origincell Biotechnology Co., Ltd., Liaoning Aimei Bio-vaccine Co., Ltd., and other top enterprises. Yonghui Wu has a keen market sense which allows him to effectively grasp market dynamics and market direction. He also has excellent coordination, communication, media management and public relations skills. During his tenure at Sanofi-Pasteur, he formed and managed a team of more than 60 people, responsible for several times increase in regional sales over four years.
Yunli XU was appointed as vice president of vaccine research and development in 2020. He is in charge of the R&D of viral and genetic products, as well as the construction and management of GMP pilot plants. With over 30 years of experience in the field of biotechnology, Mr. Xu has led multiple pre-clinical trial projects on gene therapy and is proficient in GMP pilot plant design, sample preparation and manufacturing verification. He used to serve as director in the NIP Pharm and general manager in Vector Gene Technology Company Ltd., Mr. Xu holds a degree of biology from Wuhan University and a degree of genetic engineering and molecular biology from Otsuka Pharmaceutical Co., Ltd.